Discovery of Dengue Virus Inhibitors

Area of Science:

• Virology
• Drug Discovery
• Infectious Diseases

Background:

• No approved anti-dengue agents are currently available for treating dengue virus infections.
• The existing Dengvaxia vaccine shows variable efficacy and carries risks for seronegative individuals.
• Dengue virus presents a significant global health challenge, necessitating novel therapeutic strategies.

Purpose of the Study:

• To provide an up-to-date review of dengue virus inhibitors.
• To focus on inhibitors targeting viral structural and non-structural proteins.
• To consolidate current research on potential anti-dengue drug targets within the virus itself.

Main Methods:

• Literature review of scientific studies on dengue virus inhibitors.
• Analysis of research targeting dengue virus structural proteins (C, prM, E).
• Review of studies focusing on non-structural proteins (NS1-NS5) as drug targets.

Main Results:

• Various studies have identified potential inhibitors targeting dengue virus proteins.
• Structural and non-structural proteins are key targets for antiviral drug development.
• Research is progressing in identifying specific viral components for therapeutic intervention.

Conclusions:

• Targeting dengue virus structural and non-structural proteins is a promising strategy for developing new antiviral drugs.
• Further research into these viral targets is essential for creating effective dengue treatments.
• The development of novel anti-dengue agents remains a critical unmet medical need.